Golden State Equity Partners Boosts Stake in Pfizer Inc. $PFE

Golden State Equity Partners grew its position in shares of Pfizer Inc. (NYSE:PFE) by 56.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 28,797 shares of the biopharmaceutical company’s stock after acquiring an additional 10,348 shares during the period. Golden State Equity Partners’ holdings in Pfizer were worth $698,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $27,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $28,000. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $28,000. Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $30,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.1%

NYSE:PFE opened at $24.05 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a market capitalization of $136.74 billion, a price-to-earnings ratio of 12.79, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The business has a fifty day moving average price of $24.61 and a 200-day moving average price of $24.18.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the business posted $0.60 EPS. Pfizer’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer’s dividend payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on PFE shares. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Bank of America upped their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.